Related Articles
EVALUATION OF PHAGOCYTIC-ACTIVITY IN NEOPLASTIC PATIENTS TREATED WITH SUBCUTANEOUS RECOMBINANT IL-2
COMBINED INTERLEUKIN-2 AND OKT3 THERAPY IN THE TREATMENT OF METASTATIC MELANOMA
Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19
SUBCUTANEOUS RIL-2 IN ADVANCED MELANOMA AND KIDNEY CARCINOMA
Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin